Daily Sepsis Research Analysis
Three studies advance sepsis science across mechanism, risk, and therapy. A mechanistic Immunology paper shows innate immune activation robustly suppresses CCL22, disrupting Treg–dendritic cell interactions and correlating with lower CCL22 in human sepsis. A population self-controlled case series quantifies a sharp, inflammation-graded increase in myocardial infarction and stroke risk after bloodstream infection. A propensity-matched reanalysis of the Ibuprofen in Sepsis Study links acetaminophe
Summary
Three studies advance sepsis science across mechanism, risk, and therapy. A mechanistic Immunology paper shows innate immune activation robustly suppresses CCL22, disrupting Treg–dendritic cell interactions and correlating with lower CCL22 in human sepsis. A population self-controlled case series quantifies a sharp, inflammation-graded increase in myocardial infarction and stroke risk after bloodstream infection. A propensity-matched reanalysis of the Ibuprofen in Sepsis Study links acetaminophen exposure to lower 30-day mortality and more ventilator-free days.
Research Themes
- Innate immune regulation and Treg–dendritic cell dynamics in sepsis
- Cardiovascular events triggered by bloodstream infection
- Therapeutic repurposing: acetaminophen in sepsis
Selected Articles
1. Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell-Dendritic Cell Interaction.
Innate immune activation via TLR, RLH, and STING signaling robustly suppresses CCL22 in lymphoid organs and dendritic cells, reducing regulatory T cell–dendritic cell clustering. In vivo Salmonella infection reproduced this suppression, and sepsis patients exhibited decreased serum CCL22, linking this mechanism to human disease.
Impact: This study defines a mechanistic axis by which innate immune activation transiently weakens Treg function via CCL22 suppression, providing a framework to time immunomodulatory interventions in sepsis.
Clinical Implications: CCL22 reduction in sepsis may serve as a biomarker of an early proinflammatory phase when Treg support is diminished, informing immunophenotyping and potential stage-specific immunotherapies.
Key Findings
- TLR, RLH, and STING activation strongly downregulated CCL22 expression and secretion by dendritic cells.
- Inflammatory cytokines (IFN-α, IFN-γ, IL-10) mediated CCL22 suppression following TLR activation by B and T cells.
- Reduced CCL22 correlated with fewer Treg–DC clusters in vitro; in vivo Salmonella typhimurium infection lowered CCL22 in lymphoid organs.
- Sepsis patients had significantly decreased serum CCL22 compared to controls.
Methodological Strengths
- Multiplatform approach: in vitro human and murine systems, in vivo infection models, and human clinical correlates.
- Mechanistic dissection linking PRR signaling, cytokine milieu, and functional Treg–DC interactions.
Limitations
- Predominantly preclinical mouse and in vitro data; human sample size and clinical heterogeneity not detailed.
- Causality for outcomes in human sepsis not established; interventional validation lacking.
Future Directions: Test whether modulating the CCL22–Treg–DC axis improves pathogen clearance without exacerbating immunopathology in sepsis; evaluate CCL22 as a stratification biomarker in adaptive immunotherapy trials.
The chemokine CCL22 is constitutively expressed at high levels in lymphoid organs, where it controls immunity by promoting contacts between dendritic cells (DC) and regulatory T cells (Treg). However, its regulation and impact in the context of pattern recognition receptor (PRR) stimulation and microbial infection are unknown. Here we show that CCL22 levels in lymphoid organs of mice were strongly suppressed upon stimulation with TLR agonists. In vitro, activation of Toll-like receptors (TLR), RIG-I like helicase
2. Risk of myocardial infarction and stroke following bloodstream infection: a population-based self-controlled case series.
Using a self-controlled case series in population-scale EHRs, BSI triggered a marked, time-limited increase in MI and stroke risk, peaking in the first week and normalizing by 28 days. Risk was substantially higher among those with maximal CRP >300 mg/L, indicating an inflammation-graded effect.
Impact: This quantifies cardiovascular risk windows after BSI and links risk magnitude to systemic inflammation, informing surveillance and potential preventive strategies in high-risk periods.
Clinical Implications: Clinicians should intensify cardiovascular monitoring (e.g., ECG/troponin when symptomatic, BP control) in the first 1–2 weeks after BSI, especially with high CRP. Research into targeted anti-inflammatory or antithrombotic strategies during this window is warranted.
Key Findings
- In the first 1–7 days after BSI, MI risk rose sharply (adjusted IRR 9.67, 95% CI 6.54–14.3) and returned to baseline by 28 days.
- Stroke risk was similarly elevated in the early period after BSI.
- Patients with maximal CRP >300 mg/L had the greatest risk increases (MI IRR 21.54; stroke IRR 6.94).
Methodological Strengths
- Self-controlled case series design controls for fixed individual confounders.
- Population-scale EHR linkage with inflammation stratification by maximum CRP.
Limitations
- Reliance on ICD-10 coding and timing may introduce misclassification.
- Observational design precludes causal inference; out-of-hospital events not captured.
Future Directions: Evaluate targeted anti-inflammatory or antithrombotic interventions during the high-risk window post-BSI and validate risk stratification incorporating CRP and clinical factors.
BACKGROUND: Cardiovascular disease (CVD) events triggered by inflammation are an underappreciated and poorly quantified cause of morbidity and mortality in patients with bloodstream infections (BSIs). We aimed to determine the risk of myocardial infarction (MI) and stroke after BSI. METHODS: This self-controlled case series study was conducted within the Secure Anonymised Information Linkage Databank, containing anonymised population-scale electronic health record data for Wales, UK. We included adults with community-acquired BSI between 2010 and 2020. MI and stroke were determined from International Classification of Disease Version 10 coded admissions. Predefined risk periods after BSI were compared with the baseline period using pseudo-Poisson regression adjusted for age. Maximum C-reactive protein (CRP), a proxy for the magnitude of the inflammatory response, was determined within the first 7 days after BSI. RESULTS: We identified 50 450 individuals with MI and 56 890 with stroke, of whom 1000 and 1290, respectively, also had at least one community-associated BSI. The risk of MI was most elevated in the first 1-7 days after BSI (adjusted incidence rate ratio (IRR) (95% CI): 9.67 (6.54 to 14.3)) and returned to baseline after 28 days. The risk was similarly elevated for stroke.The largest magnitude of risk was observed for those with a maximal CRP>300 mg/L (MI IRR: 21.54 (9.57 to 48.52); stroke IRR: 6.94 (3.14 to 15.32)). CONCLUSION: BSI is associated with an increased risk of CVD events in the first 2 weeks after infection. Greater systemic inflammation was associated with a higher risk of CVD events and suggests targeting the inflammatory response caused by BSI warrants further study.
3. Acetaminophen and Clinical Outcomes in Sepsis: A Retrospective Propensity Score Analysis of the Ibuprofen in Sepsis Study.
In a propensity-matched reanalysis of ISS, acetaminophen exposure within the first 2 days was associated with lower 30-day mortality (HR 0.58) and more ventilator-free days. Findings suggest a potential therapeutic effect of acetaminophen in sepsis warranting prospective trials.
Impact: Acetaminophen is inexpensive and globally available; an association with improved survival, even observational, could rapidly influence practice if validated.
Clinical Implications: Consider acetaminophen as an antipyretic in early sepsis while avoiding hepatotoxicity, recognizing that definitive efficacy requires randomized trials.
Key Findings
- Among 276 propensity-matched patients from the ISS trial, acetaminophen exposure was associated with lower 30-day mortality (HR 0.58; 95% CI 0.40–0.84).
- Acetaminophen exposure was associated with more days alive and free of mechanical ventilation.
- Analysis adjusted by propensity score included key severity and treatment assignment covariates.
Methodological Strengths
- Propensity score matching across clinically relevant covariates within a randomized trial dataset.
- Clear, patient-centered outcomes (30-day mortality, ventilator-free days).
Limitations
- Residual confounding and indication bias cannot be excluded in retrospective analyses.
- Dose, timing, and hepatotoxicity monitoring details were not reported.
Future Directions: Conduct randomized, double-blind trials testing acetaminophen in early sepsis with stratification by hemoprotein oxidation biomarkers and fever phenotype.
BACKGROUND: The Ibuprofen in Sepsis Study (ISS) randomized trial found no difference in duration of shock, ARDS, or mortality with ibuprofen treatment for sepsis. However, higher use of acetaminophen, a known hemoprotein reductant with potentially beneficial effects in sepsis, as an antipyretic in the control arm may have masked the clinical benefits from either drug. RESEARCH QUESTION: Does an association exist between administration of acetaminophen and clinical outcomes in adults with sepsis? STUDY DESIGN AND METHODS: We performed a retrospective propensity-matched analysis of the previously reported ISS trial. We created a propensity score for receiving acetaminophen during the first 2 study days using sex, age, presence of shock at enrollment, trial study drug assignment (ibuprofen or placebo), febrile status at enrollment, need for mechanical ventilation, and Acute Physiology and Chronic Health Evaluation II score at enrollment, and then matched trial participants 1:1 into acetaminophen-exposed and acetaminophen-unexposed groups based on their propensity scores. We tested the association between receipt of acetaminophen with 30-day mortality as the primary outcome. Secondary outcomes included development of renal failure and ventilator-free days (VFDs). RESULTS: Of 455 patients in the original trial, 276 patients (61%) were matched into acetaminophen-exposed and acetaminophen-unexposed groups. In the propensity-matched analysis, we found a lower mortality among acetaminophen-exposed patients compared with acetaminophen-unexposed patients (hazard ratio, 0.58; 95% CI, 0.40-0.84; INTERPRETATION: In this propensity-matched retrospective analysis, adults with sepsis who received acetaminophen showed decreased mortality and more days alive and free of mechanical ventilation. This study highlights the potential of acetaminophen as a modulator of outcomes in sepsis and warrants further investigation.